Vol. 21/No. 16

During a recent OncLive Peer Exchange®, a panel of hematology-oncology experts discussed some of the challenges surrounding the integration of biosimilars in clinical practice using the breast cancer landscape.

Considerable efforts have focused on developing agonists of costimulatory receptors, including OX40.

Early in the pandemic, the Montefiore hospital leadership had the forethought and insight to create a reliable and robust outcomes data collection system on all patients with a diagnosis of COVID-19 being seen and treated within the system.

Financial issues are among the top concerns burdening patients with cancer.

The approval of tazemetostat has expanded the portfolio of treatment options for relapsed/refractory follicular lymphoma, a disease for which new agents are needed because patients do not uniformly derive benefit from available therapies.

In an interview with OncLive, Mark G. Kris, MD discusses how the treatment of patients with metastatic lung cancer today bears scant resemblance to what it was when he entered the field 4 decades ago.

The PARP inhibitor olaparib is now available for patients with metastatic castration-resistant prostate cancer whose tumors harbor mutations in homologous recombination repair genes.

Several developments emphasize the increasing clinical relevance of germline testing within the oncology arena and the need for associated genetic counseling.